9.94
0.43 (4.52%)
| Previous Close | 9.51 |
| Open | 9.51 |
| Volume | 586,056 |
| Avg. Volume (3M) | 1,838,216 |
| Market Cap | 587,603,904 |
| Price / Earnings (TTM) | 4.95 |
| Price / Earnings (Forward) | 8.76 |
| Price / Sales | 4.57 |
| Price / Book | 2.73 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Profit Margin | -226.64% |
| Operating Margin (TTM) | -26.28% |
| Diluted EPS (TTM) | -1.94 |
| Quarterly Revenue Growth (YOY) | 495.70% |
| Total Debt/Equity (MRQ) | 150.74% |
| Current Ratio (MRQ) | 3.02 |
| Operating Cash Flow (TTM) | -61.72 M |
| Levered Free Cash Flow (TTM) | -39.23 M |
| Return on Assets (TTM) | -27.73% |
| Return on Equity (TTM) | -204.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Zevra Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.69% |
| % Held by Institutions | 65.42% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |